The heoro.com database can be used to rapidly identify economic models by geographical location. Here, we show the number of studies reporting cost-utility models in cancer by key jurisdictions, and discuss how well the focus of health economic research matches mortality data from each country.
With the increasing focus on saving money in healthcare and getting more value from services and interventions, it is now difficult for pharmaceutical companies to launch a new product internationally without demonstrating its cost-effectiveness. Conducting an economic evaluation is a common, late stage in the evidence generation plan for most new drugs or biological treatments, and is often based around a cost-utility model.
Identifying existing economic models for a specific disease is a requirement for some Health Technology Assessments, such as for the National Institute for Health and Care Excellence. Generating an evidence map of new cost-utility publications is also a way of assessing the focus of research into new treatments for diseases and how this varies by geographical setting. Yet finding relevant publications can be time-consuming, with no standard MeSH codes for different economic models or newer drug names, and geographical locations not always easy to identify.
The heoro.com database contains more than 100,000 abstracts from PubMed, published since 2005, which have been indexed by study type and methodology as well as being mapped to detailed ontologies for diseases, interventions and patient-reported outcome measures. The boolean search filter means that it is very quick to identify certain study types that have been published for selected diseases in specific locations.
The tables below show the number of abstracts of cost-utility studies indexed in the heoro.com database in June 2016, for ten common cancers across twelve countries. Finding these study counts took less than an hour – considerably less time than it would take to run specific searches of PubMed and screen the results.